In The News

Lung Therapeutics | Jun 6, 2017

Lung Therapeutics breathes easy with $14M series B

Texas startup Lung Therapeutics has got off a $14.3 million series B round as it eyes the cash boost for its trials in fibrosis, lung injury and disease.

Encore Vision | Feb 1, 2017

Encore Vision Delivers Big Payday to Angel Investors

Big winners in Novartis AG’s acquisition of Encore Vision for $465 million are members of a network of angel investors in Fort Worth, TX, that bet $4 million on the presbyopia-correcting eye drop that Encore Vision president and CEO Bill Burns has been working on for about nine years.

Cognition Therapeutics | Nov 11, 2016

Cognition Therapeutics Announces Dosing of First Alzheimer's Patient in Phase 1b Trial of CT1812

Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced today that the first Alzheimer’s patient has been dosed in a Phase 1b clinical trial of CT1812 in mild to moderate Alzheimer’s disease.

Azitra | Oct 11, 2016

Microbiome biotech joins Peter Thiel’s Breakout Labs project

The seed-stage fund Breakout Labs has added a new biotech, the skin disorder-focused Azitra, to its growing ranks of “hard science” companies.

Encore Vision | Jul 1, 2016

Treating presbyopia with an eye drop?

Minneapolis—Topical administration of lipoic acid choline ester 1.5% (EV06, Encore Vision) shows promise as a treatment for restoring accommodation to patients with presbyopia, said Richard L. Lindstrom, MD.

Encore Vision | June 14, 2016

EV06 ophthalmic solution for presbyopia improves visual outcomes in phase 1/2 study

Presbyopic patients who were treated with EV06 ophthalmic solution showed an improvement in visual outcomes in a phase 1/2 study, Encore Vision announced in a press release.

Encore Vision | May 27, 2016

Top 100 Entrepreneur of the Year: Encore is seeing clearly to future

Encore Vision Inc.’s Bill Burns has been working on a product that could solve a problem that has plagued humans for centuries.

Now, after about a decade of work, he appears within sight of realizing that goal.

Cognition Therapeutics | May 11, 2016

Pittsburgh Life Sciences Greenhouse Portfolio Company Cognition Therapeutics Wins Angel Capital Association's Luis Villabos Award

PITTSBURGH, May 11, 2016 /PRNewswire/ — Pittsburgh Life Sciences Greenhouse (PLSG), Western Pennsylvania’s only pure life sciences investment firm, announced today that premier portfolio company Cognition Therapeutics (CogRx) has been honored with the Luis Villabos Award on behalf of the Angel Capital Association (ACA), one of the most prestigious angel capital industry honors in this country.
Encore Vision | May 05, 2016

Encore Vision Announces Successful Phase I-II Study of Topical EV06 for the Treatment of Presbyopia

FORT WORTH, Texas, May 5, 2016 /PRNewswire/ — Encore Vision, Inc., a privately-held ophthalmic pharmaceutical company, presented positive results today during the Ophthalmic Innovation Summit from their Phase I-II study evaluating the safety and efficacy of EV06 ophthalmic solution 1.5%.

Encore Vision | May 03, 2016

Fort Worth startup gets positive results from clinical trials for eye drug

Encore Vision, a Fort Worth startup that has developed an eye-drop treatment for presbyopia, the hardening of a lens that causes the need for reading glasses, has received positive results from early-phase clinical trials.

Cognition Therapeutics / Lung Therapeutics | Jan 13, 2016

Five of Biotech Showcase’s most interesting startups

Presenting at the J.P. Morgan Healthcare Conference may confer some level of credibility to a company – but several worthy startups are showcased each year at the neighboring Biotech Showcase.

Encore Vision | Dec 5, 2015

Enrollment begins for phase 1/2 clinical study of topical presbyopia drug

EV06, a lipoic acid drop, is designed to reduce crystalline protein disulfide bonds, softening the lens and restoring accommodative amplitude.